The KAI KF-X is a joint South Korean and Indonesian fighter aircraft development program with the goal of producing an advanced multirole fighter for the South Korean and Indonesian air forces. The program is lead by South Korea, which holds 80% of shares. Indonesia joined in 2010 for 20%, and the remainder is held by private partners including manufacturer Korean Aerospace Industries (KAI). The KAI KF-X is South Korea's second domestic fighter jet development program, following the FA-50. The KF-X development program is also known as Boramae (보라매, Korean for "hawk"), and in Indonesia is sometimes referred to as IF-X. As of September 2019, prototypes are under construction with the first of these expected to be completed by mid-2021. The first test flight is anticipated in 2022, with manufacturing scheduled to begin in 2026. South Korea expects to deploy 120 of the aircraft into service by 2032.

WikiProject Radio Stations articles

Hospital articles needing coordinates

Piper (plant)

Gam-COVID-Vac (Russian: Гам-КОВИД-Вак, romanized Gam-KOVID-Vak), nicknamed Sputnik V, is a COVID-19 vaccine candidate. It was developed by Gamaleya Research Institute of Epidemiology and Microbiology and had limited registration in Russia on 11 August 2020 by the Russian Ministry of Health. As of 8 August 2020, no reputable scientific report on the Gam-COVID-Vac candidate had been published. Russian officials claimed that at least 20 countries are interested in obtaining the Russian vaccine. According to the Russian Direct Investment Fund, Russia will be able to produce more than 500 million doses a year in five countries. Protest developed in the international scientific community over the announcement of the vaccine registration in Russia, mainly because there has been no publication of results from clinical trials on Gam-COVID-Vac. There exists no evidence for the safety, effective dose, biomarkers of an immune response, or efficacy against COVID-19 infection. While it was announced that Gam-COVID-Vac would begin Phase III testing during 2020, no Phase I or Phase II results have been published under peer review, while six other vaccine candidates are already in interventional Phase III trials, and 26 vaccine candidates in total are in various stages of human trials. In most countries, vaccine candidates are not approved or licensed until safety and efficacy are reviewed internationally by regulators.
Gam-COVID-Vac (Russian: Гам-КОВИД-Вак, romanized Gam-KOVID-Vak), nicknamed Sputnik V, is a COVID-19 vaccine candidate. It was developed by Gamaleya Research Institute of Epidemiology and Microbiology and had limited registration in Russia on 11 August 2020 by the Russian Ministry of Health. As of 8 August 2020, no reputable scientific report on the Gam-COVID-Vac candidate had been published. Russian officials claimed that at least 20 countries are interested in obtaining the Russian vaccine. According to the Russian Direct Investment Fund, Russia will be able to produce more than 500 million doses a year in five countries.

The KAI KF-X is a joint South Korean and Indonesian fighter aircraft development program with the goal of producing an advanced multirole fighter for the South Korean and Indonesian air forces. The program is lead by South Korea, which holds 80% of shares. Indonesia joined in 2010 for 20%, and the remainder is held by private partners including manufacturer Korean Aerospace Industries (KAI). The KAI KF-X is South Korea's second domestic fighter jet development program, following the FA-50.

NA-importance Radio station articles

Gam-COVID-Vac

Xavier Musca

Wikipedia articles with undisclosed paid content from August 2020

KAI KF-X